Brought to you by:
ISET 2022 audience hears latest data on endovascular therapies
At this year’s International Symposium on Endovascular Therapy (ISET), being held Jan. 16–19 in Hollywood, Florida, experts presented an array of late-breaking trial results on topics ranging from venous stenting to abdominal aortic aneurysm (AAA) sac sealing. Waseem Wahood, MS, a…
CLI at a crossroads: Which direction now?
Vascular surgery once again finds itself at a crossroads, Michael Belkin, MD, chief of the division of vascular and endovascular surgery at Brigham and Women’s Hospital in Boston, told the Western Vascular Society (WVS) annual meeting (Oct. 16–19) in Jackson…
First patient enrolled in Disrupt BTK II study for long, calcified, below-the-knee lesions
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the Shockwave peripheral intravascular lithotripsy (IVL) system for the treatment of calcified peripheral lesions below the knee (BTK), including some…
Philips announces large-scale study outcomes on use of IVUS in peripheral interventions
Royal Philips has announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health outcomes of peripheral vascular interventions guided by intravascular ultrasound (IVUS). The study was conducted independently by…
WIfI system helps predict revascularization benefit for diabetic patients with CLTI, study finds
A retrospective study supports the use of the Wound, ischemia, and foot infection (WIfI) classification system to predict the revascularization benefit for diabetic patients with chronic limb-threatening ischemia (CLTI). The WIfI classification system was developed to stratify the risk of major amputation at one…
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for both amputation-free survival and wound healing, a press release reports. The late-breaking data were presented at…
VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel beds
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and subgroups of patients, Ehrin J. Armstrong, MD, medical director at Adventist Heart and Vascular Institute in…
‘Proceed cautiously in use of DCBs in CLTI patients with advanced WIfI stage’
The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial disease (PAD). The latest contribution from Konstantinos Katsanos, MD, and colleagues raises questions about potential increased…
PAD: R3 Vascular reports ‘successful initiation’ of first-in-human study of bioresorbable sirolimus-eluting scaffold
Medical device developer R3 Vascular has reported the “successful initiation” of a first-in-human clinical study evaluating the technical and clinical performance of its Magnitude bioresorbable sirolimus-eluting scaffold (BRS) in patients with critical limb ischemia (CLI) due to occlusive below-the-knee (BTK)…
VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism
A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional radiologist Konstantinos Katsanos, MD, that reported a heightened risk of major amputation after use of paclitaxel-coated balloons…